GBI Research's latest report, ""Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets"" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.
Payers continue to play an important role in market access. Products are increasingly being rejected for reimbursement, adversely affecting the market share of these products.
HEOR plays a critical part in market access
HTA has gained importance in reimbursement decisions
Pricing and reimbursement are the key elements of market access
Reasons to buy
This report will allow you to -
Table of Content
Health Economic and Outcomes Research (HEOR)
A Systemic Value Development Plan for HEOR
Types of Economic Evaluations
Overview of Cost-Effectiveness Analysis
Quality-Adjusted Life Year in HEOR
Pharmacoeconomic Modelling Methods
Health Technology Assessment (HTA) in Market Access
Key Benefits of HTA
Process and Dimensions of HTA
Principle HTA Regulatory Agencies
Risk Sharing Agreements When Limited Evidence is Available for HTA
Pricing and Reimbursement
Factors Affecting Pricing Decision
Pricing of a New Drug
Pharmaceutical Pricing Policies in the US
Impact Of Affordable Care Act on Market Access
Pharmaceutical Pricing and Reimbursement Policies in Canada
Pharmaceutical Pricing and Reimbursement Policies in Europe (UK, Germany, France, Italy and Spain)
Parallel Trade in Europe
Pharmaceutical Pricing and Reimbursement Policies in Japan
Economic Analysis Alongside Clinical Trials
Harmonization of Drug Approval and Marketing for Effective Market Access
Key Challenges for Achieving Optimum Market Access
Make an enquiry before buying this Report
Please fill the enquiry form below.
SCOPE OF THE REPORT This report is an effort to identify factors, which will be the driving force behind the digital radiology market and sub-markets in the next six years. This report is specially designed to estimate and analyze the demand and performance of Mexican digital radiology market. The report provides extensive analysis of the digital radiology industry, current market trends, industry drivers and challenges for better unde...
The report contains the global scenario of Vaccine market discussing its details and market figures. The report provides market size and forecast till 2016 for each segment and geography across the globe. It also describes the key influencing factors for the global vaccine market. The report lists mergers & acquisitions among the major players along with key product developments in the market. The report also provides information a...
B-type natriuretic peptides, also called, brain natriuretic peptide, is a 32-amino acid (AA) polypeptide, which is produced by ventricles of the heart, as a reflex action to over-stretching of cardiac muscles cells. The generation of BNP is controlled by calcium ions. BNP and ANP (atrial natriuretic peptide) are working similarly and the physiological action of both is similar. The important function of ANP and BNP is to decrease the systemic vas...